MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
−Removed: As of December 31, 2024, there were 24 holders of record of our common stock.
+Added: Market and Stockholder Information
+Added: Our common stock trades on The Nasdaq Global Market under the symbol “ARDX.” As of December 31, 2025, there were 23 holders of record of our common stock.
We have never declared or paid cash dividends on our capital stock.
We currently intend to retain any future earnings to finance the growth and development of our business.
−Removed: Securities Authorized for Issuance under Equity Compensation Plans
−Removed: The information required by this item regarding executive compensation will be incorporated by reference to the information set forth in the sections titled “Executive Compensation” in our Proxy Statement.
−Removed: Recent Sales of Unregistered Securities
−Removed: Use of Proceeds
−Removed: Not applicable.
Issuer Purchases of Equity Securities
Not applicable.
+Added: Stock Performance Graph
+Added: The following performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our future filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.
+Added: The graph below compares the cumulative total stockholder return on our common stock from December 31, 2020 to the end of fiscal year 2025 with the cumulative total return of (i) the Nasdaq Composite Index and (ii) the Nasdaq Biotechnology Index.
+Added: The graph assumes an initial investment value of $100 on December 31, 2020 and reinvestment of dividends.
+Added: Table of Co n t e n t s
+Added: Value of $100 invested on December 31, 2020 in stock or index, including reinvestment of dividends, for fiscal years ended December 31:
+Added: 2020 2021 2022 2023 2024 2025
+Added: Ardelyx, Inc.
+Added: $ 100.00 $ 17.00 $ 44.05 $ 95.83 $ 78.36 $ 90.11
+Added: Nasdaq Composite Index $ 100.00 $ 121.39 $ 81.21 $ 116.47 $ 149.83 $ 180.33
+Added: Nasdaq Biotechnology Index $ 100.00 $ 99.37 $ 88.53 $ 91.84 $ 90.58 $ 119.92
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.